The client challenge
Some air-treatment products arrive at the laboratory as finished devices. Glow Guardian took a different path. It began as a functional candle concept intended not only to burn, but also to release active constituents into room air and reduce viable airborne microorganisms under controlled test conditions.1,3,4
The development question did not fit a conventional air-cleaner model. A filter-based purifier draws air through media, a ducted system treats air within an HVAC path, and an in-device treatment system operates inside a housing. Glow Guardian was designed as an active-in-air product, releasing constituents into room air where they could interact with airborne microorganisms.1,3
Glow Guardian needed more than a routine pass/fail test. The project required a development pathway connecting aerosol science and formulation refinement with bioaerosol generation, viable sampling, chamber testing, and data interpretation.1
ARE Labs as development partner
ARE Labs supported Glow Guardian with formulation work, chamber challenge testing, method adaptation, and final efficacy studies. The team evaluated a candle formulation, measured the bioaerosol response, and used the results to guide formulation adjustments. This cycle was repeated many times while the product moved toward its final configuration.1
These repeated challenges were important because the performance of an active-in-air product depends on both its mechanism and the fit of the test method. Small changes in formulation, release behavior, burn characteristics, particle behavior, or active delivery can influence the results. The chamber therefore served as a development feedback tool, not only as an environment for final reporting.1,2
How the product was tested
The primary efficacy study tested the Glow Guardian air treatment candle against a broad range of respirable microorganisms in a sealed environmental bioaerosol test chamber. According to the source report, the protocol was modeled on FDA 510(k)-style testing methods for in-room air purifiers, and the work complied with Good Laboratory Practice expectations in 21 CFR Part 58.1,5
Each microorganism was aerosolized into a controlled chamber containing the candle. ARE Labs used controlled bioaerosol generation and viable sampling to track bioaerosol concentrations over time. Samples were serially diluted, plated, incubated, and enumerated. Control trials measured natural chamber decay, which was subtracted from the candle trial results to calculate net reduction.1
| Organism or surrogate | Organism type | Maximum net percent reduction | Average CADR |
|---|---|---|---|
| MS2 bacteriophage | Unenveloped RNA virus surrogate | 99.74% | 35.40 cfm |
| Phi X bacteriophage | Unenveloped DNA virus surrogate | 99.15% | 24.05 cfm |
| Staphylococcus epidermidis | Gram-positive bacterium | 99.93% | 35.29 cfm |
| Listeria innocua | Gram-positive bacterium | 99.97% | 35.87 cfm |
| Klebsiella aerogenes | Gram-negative bacterium | 99.99% | 46.17 cfm |
| Pseudomonas syringae | Gram-negative bacterium | 99.78% | 47.32 cfm |
| Aspergillus brasiliensis | Mold spores | 81.84% | 12.23 cfm |
| Bacillus subtilis | Bacterial endospores | 34.84% | 3.53 cfm |
Broad-spectrum results
The final broad-range study measured efficacy across every organism group tested. For most non-spore organisms, the Glow Guardian candle achieved a maximum net percent reduction greater than 99% during the two-hour chamber test period after correction for control decay. More resistant organisms, including mold spores and bacterial endospores, showed lower reductions.1
Source: client-approved ARE Labs broad-range bioaerosol efficacy report summary.
- Organism names are shortened in the chart labels for readability.
- Values are control-corrected maximum net percent reductions from the source article.
The organism-dependent results added important context by showing that the biological challenges did not respond equally. Gram-negative bacteria and virus surrogates showed high reductions, while mold spores and bacterial endospores were more resistant. This pattern is consistent with the greater environmental durability of spores and endospores.1
The first-minute question
Because Glow Guardian was designed as an active-in-air product, the program raised a second question: What happens immediately after a bioaerosol enters a room that has already been pretreated? With filtration, in-device UV, and many recirculating air cleaners, contaminated air generally must enter the device or treatment zone. When active material is already distributed throughout a room, performance during the earliest part of an aerosol event may also matter.2
ARE Labs examined this scenario in a separate pretreatment study. The candle was lit before the bioaerosol was introduced. After a defined pretreatment period, the organisms were aerosolized into the chamber, and viable concentrations were measured following one minute of chamber mixing.2
| Pretreatment challenge organism | Organism type | Net percent reduction after one minute |
|---|---|---|
| MS2 bacteriophage | Unenveloped RNA virus surrogate | 90.66% |
| Klebsiella aerogenes | Gram-negative bacterium | 41.75% |
| Staphylococcus epidermidis | Gram-positive bacterium | 30.80% |
The pretreatment study is summarized here because it shaped the active-in-air method story.
Business impact
Glow Guardian received more than a final test report. By the end of the program, the client had advanced a functional candle formulation from concept toward product readiness. The supporting evidence included broad-range viable bioaerosol efficacy data, one-minute room-pretreatment data, and a public-facing science story based on independent laboratory reports.1,2,3
That distinction matters to buyers, partners, retailers, and investors. A novel consumer air-treatment product needs more than a general claim that it works. It needs evidence showing that the mechanism can be challenged, measured, repeated, and explained without extending the product story beyond the boundaries of the test data.1,3
The public patent record identifies U.S. Patent No. 12,467,016 B1, titled Air purification candle, and lists Glow Guardian as the assignee. This patent provides relevant context for the success story: the laboratory work, iterative product-development process, and public IP record reflect the same broader outcome. A novel product moved from an initial concept to a documented technical position.4
What this says about method fit
Many laboratories can run a standard method. Product development becomes more demanding when the method must be adapted to match how the product works. Glow Guardian's program required aerosol generation, viable bioaerosol sampling, chamber design, particle behavior, formulation support, and GLP-aligned reporting to function as one coordinated development process.1,5
The broader lesson applies to other aerosol and air-treatment developers. When a product relies on airborne actives, room-scale interactions, or nontraditional release behavior, the testing plan should reflect its intended mechanism rather than defaulting to the nearest familiar test category. Otherwise, valuable development signals may be overlooked or misinterpreted.1,2
Summary
Glow Guardian needed more than final validation. The client needed a development partner capable of testing, interpreting, and refining a novel active-in-air product concept. ARE Labs connected formulation iteration with room-scale bioaerosol challenge methods, control-corrected efficacy data, and careful claim boundaries. The result was a public success story grounded in measured evidence.1,2